$XLRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACCELERON PHARMA INC. Get notifications about new insider transactions in ACCELERON PHARMA INC for free.
Page: < prev 1 ... 3 4 5 6 7 8 9 10 11 ... 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 40.62 | 1,034 | 42,001 | 33,666 | 34.7 K to 33.7 K (-2.98 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 42.06 | 300 | 12,618 | 34,700 | 35 K to 34.7 K (-0.86 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 41.22 | 1,614 | 66,529 | 35,000 | 36.6 K to 35 K (-4.41 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 40.56 | 2,086 | 84,608 | 36,614 | 38.7 K to 36.6 K (-5.39 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 3,500 | 20,580 | 38,700 | 35.2 K to 38.7 K (+9.94 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 500 | 2,940 | 35,200 | 34.7 K to 35.2 K (+1.44 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | A | 41.01 | 15,000 | 615,150 | 15,000 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.08 | 1,600 | 8,128 | 26,296 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 24,000 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.38 | 300 | 12,414 | 17,700 | 18 K to 17.7 K (-1.67 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 40.63 | 700 | 28,441 | 18,000 | 18.7 K to 18 K (-3.74 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 40.92 | 400 | 16,368 | 18,700 | 19.1 K to 18.7 K (-2.09 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 40.21 | 1,600 | 64,336 | 20,004 | 21.6 K to 20 K (-7.41 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.08 | 1,600 | 8,128 | 21,604 | 20 K to 21.6 K (+8.00 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 42.07 | 200 | 8,414 | 20,004 | 20.2 K to 20 K (-0.99 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.40 | 1,001 | 41,441 | 20,204 | 21.2 K to 20.2 K (-4.72 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 40.66 | 2,799 | 113,807 | 21,205 | 24 K to 21.2 K (-11.66 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 24,004 | 20 K to 24 K (+20.00 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | A | 41.01 | 30,000 | 1,230,300 | 30,000 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 5.08 | 3,906 | 19,842 | 2,344 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 1.80 | 1,094 | 1,969 | 0 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 42.05 | 400 | 16,820 | 52,656 | 53.1 K to 52.7 K (-0.75 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 41.28 | 2,043 | 84,335 | 53,056 | 55.1 K to 53.1 K (-3.71 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 40.54 | 2,557 | 103,661 | 55,099 | 57.7 K to 55.1 K (-4.43 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 5.08 | 3,906 | 19,842 | 57,656 | 53.8 K to 57.7 K (+7.27 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 1.80 | 1,094 | 1,969 | 53,750 | 52.7 K to 53.8 K (+2.08 %) |
| Feb 11 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 1,500 | 5,820 | 97,251 | |
| Feb 11 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 98,751 | |
| Feb 11 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 36.65 | 1,500 | 54,975 | 25,000 | 26.5 K to 25 K (-5.66 %) |
| Feb 11 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 1,500 | 5,820 | 26,500 | 25 K to 26.5 K (+6.00 %) |
| Feb 11 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 37.11 | 400 | 14,844 | 25,000 | 25.4 K to 25 K (-1.57 %) |
| Feb 11 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 36.60 | 4,600 | 168,360 | 25,400 | 30 K to 25.4 K (-15.33 %) |
| Feb 11 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 30,000 | 25 K to 30 K (+20.00 %) |
| Feb 11 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 37.20 | 1,937 | 72,056 | 47,584 | 49.5 K to 47.6 K (-3.91 %) |
| Feb 11 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 36.59 | 18,063 | 660,925 | 49,521 | 67.6 K to 49.5 K (-26.73 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 1.80 | 5,000 | 9,000 | 1,094 | |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 39.95 | 300 | 11,985 | 52,656 | 53 K to 52.7 K (-0.57 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 39.03 | 1,900 | 74,157 | 52,956 | 54.9 K to 53 K (-3.46 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 38.33 | 2,800 | 107,324 | 54,856 | 57.7 K to 54.9 K (-4.86 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 1.80 | 5,000 | 9,000 | 57,656 | 52.7 K to 57.7 K (+9.50 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 500 | |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 39.46 | 300 | 11,838 | 34,700 | 35 K to 34.7 K (-0.86 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 38.56 | 1,200 | 46,272 | 35,000 | 36.2 K to 35 K (-3.31 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 39.13 | 1,435 | 56,152 | 36,200 | 37.6 K to 36.2 K (-3.81 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 38.39 | 2,565 | 98,470 | 37,635 | 40.2 K to 37.6 K (-6.38 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 40,200 | 36.2 K to 40.2 K (+11.05 %) |
| Jan 28 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Gift | G | 0.00 | 1,416 | 0 | 67,584 | 69 K to 67.6 K (-2.05 %) |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 28,000 | |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 5.08 | 1,600 | 8,128 | 27,896 | |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 41.60 | 1,000 | 41,600 | 19,100 | 20.1 K to 19.1 K (-4.98 %) |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 41.70 | 400 | 16,680 | 20,100 | 20.5 K to 20.1 K (-1.95 %) |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 41.81 | 2,486 | 103,940 | 24,004 | 26.5 K to 24 K (-9.38 %) |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 41.23 | 1,514 | 62,422 | 22,490 | 24 K to 22.5 K (-6.31 %) |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 24,004 | 20 K to 24 K (+20.00 %) |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 41.78 | 1,600 | 66,848 | 20,004 | 21.6 K to 20 K (-7.41 %) |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 5.08 | 1,600 | 8,128 | 21,604 | 20 K to 21.6 K (+8.00 %) |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 0.40 | 12,500 | 5,000 | 0 | |
| Jan 22 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 0.40 | 12,500 | 5,000 | 69,000 | 56.5 K to 69 K (+22.12 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 2,438 | 14,335 | 6,961 | |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.08 | 1,500 | 7,620 | 6,000 | |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 1,562 | 8,247 | 12,145 | |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 1.80 | 500 | 900 | 2,000 | |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 3,500 | 3,220 | 0 | |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.12 | 5,500 | 220,660 | 15,000 | 20.5 K to 15 K (-26.83 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 2,438 | 14,335 | 20,500 | 18.1 K to 20.5 K (+13.50 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.08 | 1,500 | 7,620 | 18,062 | 16.6 K to 18.1 K (+9.06 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 1,562 | 8,247 | 16,562 | 15 K to 16.6 K (+10.41 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.62 | 500 | 20,310 | 15,000 | 15.5 K to 15 K (-3.23 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 39.85 | 3,500 | 139,475 | 15,500 | 19 K to 15.5 K (-18.42 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 1.80 | 500 | 900 | 19,000 | 18.5 K to 19 K (+2.70 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 3,500 | 3,220 | 18,500 | 15 K to 18.5 K (+23.33 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 3.88 | 2,000 | 7,760 | 35,500 | |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 41.05 | 200 | 8,210 | 52,656 | 52.9 K to 52.7 K (-0.38 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 40.53 | 1,800 | 72,954 | 52,856 | 54.7 K to 52.9 K (-3.29 %) |
| Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 3.88 | 2,000 | 7,760 | 54,656 | 52.7 K to 54.7 K (+3.80 %) |
| Jan 13 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 41.06 | 1,100 | 45,166 | 36,200 | 37.3 K to 36.2 K (-2.95 %) |
| Jan 13 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 40.09 | 400 | 16,036 | 37,300 | 37.7 K to 37.3 K (-1.06 %) |
| Jan 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 2,000 | 7,760 | 103,751 | |
| Jan 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 41.04 | 845 | 34,679 | 25,000 | 25.8 K to 25 K (-3.27 %) |
| Jan 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 40.38 | 1,155 | 46,639 | 25,845 | 27 K to 25.8 K (-4.28 %) |
| Jan 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 2,000 | 7,760 | 27,000 | 25 K to 27 K (+8.00 %) |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 41.20 | 576 | 23,731 | 576 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Option Exercise | A | 41.20 | 4,665 | 192,198 | 4,665 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Option Exercise | A | 41.20 | 10,000 | 412,000 | 10,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | A | 41.20 | 10,000 | 412,000 | 10,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | A | 41.20 | 10,000 | 412,000 | 10,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | A | 41.20 | 10,000 | 412,000 | 10,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | A | 41.20 | 10,000 | 412,000 | 10,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Option Exercise | A | 41.20 | 10,000 | 412,000 | 10,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | A | 41.20 | 41,000 | 1,689,200 | 41,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | A | 41.20 | 41,000 | 1,689,200 | 41,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | A | 41.20 | 41,000 | 1,689,200 | 41,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | A | 41.20 | 41,000 | 1,689,200 | 41,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 41.20 | 41,000 | 1,689,200 | 41,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 105,751 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 39.59 | 4,300 | 170,237 | 25,000 | 29.3 K to 25 K (-14.68 %) |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 38.67 | 700 | 27,069 | 29,300 | 30 K to 29.3 K (-2.33 %) |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 30,000 | 25 K to 30 K (+20.00 %) |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | A | 41.20 | 151,000 | 6,221,200 | 151,000 | |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 39.66 | 18,800 | 745,608 | 56,500 | 75.3 K to 56.5 K (-24.97 %) |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 38.93 | 1,200 | 46,716 | 75,300 | 76.5 K to 75.3 K (-1.57 %) |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 1.80 | 5,000 | 9,000 | 6,094 | |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 39.36 | 700 | 27,552 | 52,656 | 53.4 K to 52.7 K (-1.31 %) |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 38.32 | 4,300 | 164,776 | 53,356 | 57.7 K to 53.4 K (-7.46 %) |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 1.80 | 5,000 | 9,000 | 57,656 | 52.7 K to 57.7 K (+9.50 %) |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 4,500 | |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 39.37 | 400 | 15,748 | 37,700 | 38.1 K to 37.7 K (-1.05 %) |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 38.36 | 3,600 | 138,096 | 38,100 | 41.7 K to 38.1 K (-8.63 %) |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 41,700 | 37.7 K to 41.7 K (+10.61 %) |
| Dec 29 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 38.00 | 3,187 | 121,106 | 0 | 3.2 K to 0 (-100.00 %) |
| Dec 29 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 38.00 | 51,163 | 1,944,194 | 0 | 51.2 K to 0 (-100.00 %) |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 3.88 | 15,000 | 58,200 | 36,240 | |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 3.88 | 15,000 | 58,200 | 15,000 | 0 to 15 K |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 1.80 | 5,825 | 10,485 | 7,300 | |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 0.92 | 3,985 | 3,666 | 0 | |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 1.80 | 5,825 | 10,485 | 37,700 | 31.9 K to 37.7 K (+18.27 %) |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 0.92 | 3,985 | 3,666 | 31,875 | 27.9 K to 31.9 K (+14.29 %) |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 32,000 | |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 3.88 | 2,000 | 7,760 | 35,500 | |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 40.19 | 1,000 | 40,190 | 20,500 | 21.5 K to 20.5 K (-4.65 %) |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 40.60 | 200 | 8,120 | 20,004 | 20.2 K to 20 K (-0.99 %) |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 40.13 | 3,800 | 152,494 | 20,204 | 24 K to 20.2 K (-15.83 %) |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 24,004 | 20 K to 24 K (+20.00 %) |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 3.88 | 2,000 | 7,760 | 20,004 | 18 K to 20 K (+11.11 %) |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 15,000 | 58,200 | 110,751 | |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 15,000 | 58,200 | 25,000 | 10 K to 25 K (+150.00 %) |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | J | 0.00 | 23,867 | 0 | 28,734 | 4.9 K to 28.7 K (+490.38 %) |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | J | 0.00 | 23,867 | 0 | 251 | 24.1 K to 251 (-98.96 %) |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | J | 0.00 | 13,136 | 0 | 13,136 | 0 to 13.1 K |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | J | 0.00 | 13,136 | 0 | 24,118 | 37.3 K to 24.1 K (-35.26 %) |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | J | 0.00 | 712 | 0 | 37,254 | 36.5 K to 37.3 K (+1.95 %) |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | J | 0.00 | 36,542 | 0 | 36,542 | 0 to 36.5 K |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | J | 0.00 | 3,187 | 0 | 3,187 | 0 to 3.2 K |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | J | 0.00 | 51,163 | 0 | 51,163 | 0 to 51.2 K |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | J | 0.00 | 60,496 | 0 | 30,248 | 90.7 K to 30.2 K (-66.67 %) |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | J | 0.00 | 500,421 | 0 | 500,420 | 1 M to 500.4 K (-50.00 %) |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 4,000 | 3,680 | 3,500 | |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.72 | 2,500 | 104,300 | 0 | 2.5 K to 0 (-100.00 %) |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.72 | 1,500 | 61,080 | 2,500 | 4 K to 2.5 K (-37.50 %) |
| Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 4,000 | 3,680 | 4,000 | 0 to 4 K |
| Dec 15 2014 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | J | 0.00 | 403,166 | 0 | 2,218,572 | 2.6 M to 2.2 M (-15.38 %) |
| Dec 12 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 5.08 | 4,000 | 20,320 | 29,496 | |
| Dec 12 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 43.73 | 500 | 21,865 | 21,500 | 22 K to 21.5 K (-2.27 %) |
| Dec 12 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 43.16 | 500 | 21,580 | 22,000 | 22.5 K to 22 K (-2.22 %) |
| Dec 12 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 43.88 | 1,065 | 46,732 | 18,004 | 19.1 K to 18 K (-5.58 %) |
| Dec 12 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 43.32 | 2,935 | 127,144 | 19,069 | 22 K to 19.1 K (-13.34 %) |
| Dec 12 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 5.08 | 4,000 | 20,320 | 22,004 | 18 K to 22 K (+22.22 %) |
| Dec 12 2014 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 41.48 | 20,000 | 829,600 | 20,000 | |
| Dec 10 2014 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 40.11 | 8,778 | 352,086 | 1,310,650 | 1.3 M to 1.3 M (-0.67 %) |
| Dec 10 2014 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 46.02 | 5,486 | 252,466 | 1,814,434 | 1.8 M to 1.8 M (-0.30 %) |